Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
MWN-AI** Summary
Serina Therapeutics, Inc., a clinical-stage biotechnology company, has announced a significant milestone in its clinical development program by dosing the first patient in its Phase 1b registrational trial of SER-252, a novel treatment for advanced Parkinson's disease. This trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients whose symptoms remain inadequately controlled by existing therapies.
The company's strategic approach leverages its proprietary POZ Platform™, designed for drug optimization. By aligning with the FDA on a 505(b)(2) New Drug Application pathway and designating this Phase 1b study as registrational, Serina is poised to efficiently gather the clinical data necessary for SER-252's market application. CEO Steve Ledger emphasized the importance of this development and the ongoing support from clinical investigators and the Parkinson's community in Australia, highlighting strong collaboration for patient identification and enrollment.
The blinded safety and tolerability evaluation by the Safety Monitoring Committee from Cohort 1 is expected to lead to the advancement of the trial to Cohort 2 by the third quarter of 2026. Initial dosing is taking place at global clinical sites, particularly in Australia.
SER-252 is based on apomorphine therapy and aims to provide continuous dopaminergic stimulation, which could mitigate levodopa-induced motor complications in Parkinson's patients. The company is optimistic about the potential of SER-252, further underscored by promising preclinical studies that indicate it could deliver benefits without adverse skin reactions.
As Serina advances its clinical programs, it plans to keep stakeholders informed about trial updates and progress. With a compelling drug delivery technology and strategic partnerships, Serina Therapeutics is actively working to address significant medical needs in neurology.
MWN-AI** Analysis
Serina Therapeutics, Inc. (NYSE American: SER) recently marked a critical milestone in its clinical journey by dosing the first patient in a Phase 1b registrational trial for SER-252, an investigational drug aimed at addressing advanced Parkinson's disease. This development is pivotal given the urgent need for improved therapies for patients whose symptoms remain inadequately controlled by existing treatments.
The company's proprietary POZ Platform™ enables Serina to optimize drug candidates effectively, positioning it as a potential leader in the biopharmaceutical landscape focused on neurological disorders. Given the anticipated safety and tolerability data from the Safety Monitoring Committee, analysts should watch for significant updates as the trial progresses, particularly with the potential advancement to Cohort 2 projected for the third quarter of 2026.
The strategic partnership with Parkinson's Australia underscores Serina's commitment to a robust patient recruitment strategy, which is a crucial factor in clinical trial success. With the FDA's alignment on the 505(b)(2) NDA pathway for regulatory submission, Serina’s efficient capital development strategy may reduce time-to-market and costs typically involved in drug development.
Investors should remain vigilant on the company's clinical trial milestones and patient enrollment updates, as these will be key indicators of SER-252's potential. Encouraging data could drive market interest, especially given the increasing demand for innovative Parkinson's treatments. Additionally, any favorable FDA interactions could enhance investor confidence, potentially leading to price appreciation.
However, it’s essential to keep in mind the inherent risks associated with clinical trials, including variables that may affect SER-252’s timelines and viability. A cautious approach, aligning your investment with ongoing clinical developments and regulatory news, will be prudent for those considering entering Serina Therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –
- Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ -
HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, today announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.
The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina anticipates that blinded review of safety and tolerability by the Safety Monitoring Committee from Cohort 1 will allow advancement to Cohort 2 in the third quarter of 2026.
“Dosing the first patient represents an important inflection point for Serina as we begin generating clinical data with SER-252,” said Steve Ledger, Chief Executive Officer of Serina. "With FDA alignment on our 505(b)(2) NDA pathway and recognition of this Phase 1b trial as registrational, we are positioned to efficiently generate the clinical data necessary to bring SER-252 to market. We are grateful to our clinical investigators, the Parkinson's community in Australia, and the patients who are making this trial possible."
Serina has established relationships with Parkinson's Australia and Neuroscience Trials Australia to support patient identification and enrollment activities. The Company plans to provide further updates on the trial as patient enrollment progresses.
Initial dosing activities are underway at global clinical sites, including Australia, where Serina has established strong investigator relationships to support efficient trial execution. The Company expects to provide additional clinical and operational updates as the study advances.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
About the POZ Platform™
Serina's proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina's POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina's product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina's POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina's POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About SER-252 (POZ-apomorphine)
SER-252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson's disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions.
Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of federal securities laws. All statements that are not historical fact, including statements about Serina's planned clinical programs, including timing for patient enrollment and dosing, the potential of Serina's POZ polymer technology, and the Company's ability to advance its clinical trial, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.
Actual results may differ materially from those projected in such statements due to a variety of important factors including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina's ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and the company's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ**
How does Serina Therapeutics Inc. SER plan to ensure the safety and tolerability of SER-252 during the evaluation by the Safety Monitoring Committee, and what measures are in place to address potential adverse events?
What specific milestones does Serina Therapeutics Inc. SER anticipate achieving by the advancement to Cohort 2 in Q3 2026, and how will these milestones impact the overall timeline of the SER-252 development program?
How does Serina Therapeutics Inc. SER's capital-efficient development strategy leveraging the POZ Platform™ differentiate it from competitors in the market for Parkinson's disease treatments?
What feedback has Serina Therapeutics Inc. SER received from regulatory authorities regarding the Phase 1b registrational study design, and how does this align with the company's 505(b)(2) NDA pathway strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Serina Therapeutics Inc. (NYSE: SER).
NASDAQ: SER
SER Trading
-4.11% G/L:
$2.402 Last:
11,759,839 Volume:
$2.80 Open:
